SCHEMBL2028307

SCHEMBL2028307

CCN(C(=O)O)[C@@H](CS)C(=O)O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.34
SLC7A11 Q9UPY5 1/20 0.34
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
THRB P10828 1/20 0.33
ALOX15 P16050 1/20 0.33
NFKB1 P19838 1/20 0.33
PTGS2 P35354 1/20 0.33
THPO P40225 1/20 0.33
RECQL P46063 1/20 0.33
BLM P54132 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ENPEP Q07075 4/20 0.32
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.31
POLB P06746 1/20 0.31
HSD17B10 Q99714 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
ACE P12821 1/20 0.31
FOLH1 Q04609 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL515406 1.00 PTGS1 (0.34) PTGS1SLC7A11KDM4EMAPTTHRB
SCHEMBL7360975 1.00 PTGS1 (0.34) PTGS1SLC7A11KDM4EMAPTTHRB
SCHEMBL38660143 0.85 KDM4E (0.36) PTGS1SLC7A11KDM4EMAPTTHRB
SCHEMBL3230289 0.85 KDM4E (0.36) PTGS1SLC7A11KDM4EMAPTTHRB
SCHEMBL7646334 0.85 KDM4E (0.36) PTGS1SLC7A11KDM4EMAPTTHRB
SCHEMBL8276211 0.82 ALDH1A1 (0.33) ALDH1A1LMNAPOLBHSD17B10L3MBTL1
SCHEMBL4632069 0.79 PTGS1 (0.47) PTGS1SLC7A11ENPEP
SCHEMBL3858823 0.78 TDP1 (0.37) MAPTSMN1; SMN2ALDH1A1LMNAPOLB
SCHEMBL11109011 0.77 ALDH1A1 (0.39) SMN1; SMN2ALDH1A1LMNAPOLBHSD17B10
SCHEMBL20512314 0.77 PTGS1 (0.37) PTGS1SLC7A11KDM4EMAPTTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250367300-A1 Nanomaterial and Methods of Use Thereof UNIVERSITY OF CONNECTICUT (US) 2025-12-04 US disclosed
US-20250302762-A1 NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF UNIVERSITY OF CONNECTICUT (US) 2025-10-02 US disclosed
US-20250302971-A1 Therapeutic Nanomaterials UNIV CONNECTICUT (US) 2025-10-02 US disclosed
US-20250229081-A1 NANOMATERIAL COATED ELECTRODE AND METHODS OF USE THEREOF UNIVERSITY OF CONNECTICUT 2025-07-17 US disclosed
CN-120202010-A Ligand-oligonucleotide conjugates and linkers for use therewith 上海京新生物医药有限公司 2025-06-24 CN disclosed
US-20250084410-A1 INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF Synthorx, Inc. (US) 2025-03-13 US disclosed
US-20250066799-A1 UNNATURAL BASE PAIR COMPOSITIONS AND METHODS OF USE THE SCRIPPS RESEARCH INSTITUTE 2025-02-27 US disclosed
EP-4504732-A2 NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF University of Connecticut (US) 2025-02-12 EP disclosed
US-12214043-B2 Therapeutic nanomaterials UNIVERSITY OF CONNECTICUT 2025-02-04 US disclosed
US-12173291-B2 Unnatural base pair compositions and methods of use THE SCRIPPS RESEARCH INSTITUTE (US) 2024-12-24 US disclosed
US-8343475-B2 Small cationic antimicrobial peptides THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2013-01-01 US disclosed
US-20110236429-A1 Small Cationic Antimicrobial Peptides THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2011-09-29 US disclosed
US-20110150917-A1 Small Cationic Antimicrobial Peptides THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2011-06-23 US disclosed
EP-2061886-A1 SMALL CATIONIC ANTIMICROBIAL PEPTIDES The University of British Columbia (CA) 2009-05-27 EP disclosed
WO-2008151434-A1 SMALL CATIONIC ANTIMICROBIAL PEPTIDES THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2008-12-18 WO disclosed
WO-2008022444-A1 SMALL CATIONIC ANTIMICROBIAL PEPTIDES THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2008-02-28 WO disclosed
EP-0975321-A2 THE USE OF THIOGLYCOLIC ACID AS DEPIGMENTING AGENT I.V. Pharma S.A.S. (IT) 2000-02-02 EP disclosed
WO-1998047466-A2 THE USE OF THIOGLYCOLIC ACID AS DEPIGMENTING AGENT I.V. PHARMA S.A.S. (IT) 1998-10-29 WO disclosed
EP-0440633-A1 PHARMACEUTICAL FOR TREATING TUMORS IN HUMANS AND METHOD FOR MAKING IT. ALFACELL CORP (US) 1991-08-14 EP disclosed
WO-1989009606-A1 PHARMACEUTICAL FOR TREATING TUMORS IN HUMANS AND METHOD FOR MAKING IT ALFACELL CORPORATION (US) 1989-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250302971-A1 Therapeutic Nanomaterials TIE1, TEKT1, POLRMT PTGS1 3983/4885SLC7A11 2333/4885KDM4E 2272/4885
US-20250367300-A1 Nanomaterial and Methods of Use Thereof EPCAM, CD47, JAK2 PTGS1 1907/4885SLC7A11 553/4885KDM4E 848/4885
US-20250302762-A1 NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF JAK2, JAK1, CHMP4B PTGS1 2516/4885SLC7A11 254/4885KDM4E 2142/4885
US-12173291-B2 Unnatural base pair compositions and methods of use RNGTT, SPOUT1, NPEPPS PTGS1 4650/4885SLC7A11 406/4885KDM4E 4046/4885
US-20250066799-A1 UNNATURAL BASE PAIR COMPOSITIONS AND METHODS OF USE RNGTT, SPOUT1, NPEPPS PTGS1 4650/4885SLC7A11 406/4885KDM4E 4046/4885
US-20250084410-A1 INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF RNGTT, TRMT1, OSGEP PTGS1 4371/4885SLC7A11 913/4885KDM4E 3826/4885
US-12214043-B2 Therapeutic nanomaterials TIE1, TEKT1, POLRMT PTGS1 3983/4885SLC7A11 2333/4885KDM4E 2272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.